Asio Capital LLC Reduces Stake in IQVIA Holdings Inc.

Asio Capital LLC has recently reduced its investment in IQVIA Holdings Inc. (NYSE:IQV) by 59.2% during the fourth quarter, based on its latest Form 13F filing with the Securities and Exchange Commission. Following this adjustment, the fund now holds 4,304 shares of the medical research firm after selling 6,233 shares during that period. As of the end of the latest reporting cycle, Asio Capital LLC's holdings in IQVIA were valued at approximately $846,000.

In addition to Asio Capital's actions, a number of other institutional investors have also altered their positions in IQVIA recently. Capital Performance Advisors LLP acquired a new investment in IQVIA in the third quarter, estimated at around $27,000. Similarly, Park Place Capital Corp made a new purchase of shares valued at approximately $28,000 during the same period. Furthermore, Avior Wealth Management LLC increased its stake by 117.6% in the third quarter, now owning 161 shares valued at $38,000, having added 87 shares in the last quarter. Assetmark Inc. significantly raised its holding by 612.5% during the third quarter, increasing its ownership to 228 shares worth about $54,000 after acquiring an additional 196 shares. UMB Bank n.a. also increased its position by 74.4%, now holding 232 shares valued at $55,000 after buying 99 more shares during the period. Presently, institutional investors own approximately 89.62% of IQVIA's stock.

IQVIA's Stock Performance

The shares of IQVIA Holdings Inc. opened at $204.54 on the latest trading day. The stock has a 50-day simple moving average at $199.71 and a 200-day simple moving average of $221.06. Over the past year, the company's stock reached a low of $187.62 and a high of $261.73. IQVIA currently has a market capitalization of $37.12 billion, a price-to-earnings (P/E) ratio of 26.84, a price/earnings-to-growth (P/E/G) ratio of 2.14, and a beta of 1.48. Additionally, the firm has a debt-to-equity ratio of 1.76, alongside both a quick and current ratio of 0.81.

Analyst Opinions on IQVIA

Multiple brokerages have recently provided their insights on IQVIA's stock. For instance, Leerink Partners has maintained an "outperform" rating and adjusted its price target to $248.00, down from a previous forecast of $260.00. StockNews.com revised its rating from "buy" to "hold" for IQVIA shares. Deutsche Bank lowered its price target from $270.00 to $265.00, giving the stock a "buy" rating. The Goldman Sachs Group also cut its target price to $250.00, while Barclays dropped their price estimate from $260.00 to $255.00, setting an "overweight" rating as well. Overall, four analysts have rated IQVIA's stock as a hold, seventeen have given it a buy recommendation, and one has provided a strong buy rating. Based on data from MarketBeat, the stock is currently rated as a "Moderate Buy" with an average price target of $255.71.

About IQVIA Holdings Inc.

IQVIA Holdings Inc. offers advanced analytics, technology solutions, and clinical research services to the life sciences sector across the Americas, Europe, Africa, and Asia-Pacific. The company operates through three primary segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Stocks, Investment, Portfolio